Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | CDKN1A | P38936 | 1/20 | 0.40 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.40 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.40 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CRACR2A | Q9BSW2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22060741 | 0.90 | CDKN1A (0.52) | MAPTCDKN1AMAPK1TP53 | |
| SCHEMBL22060716 | 0.89 | LMNA (0.46) | TDP1NR3C1CDKN1ASCN2ASCN10A | |
| SCHEMBL22060133 | 0.88 | NR3C1 (0.48) | NR3C1CDKN1AP2RY1SMN1; SMN2 | |
| SCHEMBL22060343 | 0.88 | KDR (0.45) | MAPTTDP1NR3C1CDKN1AMAPK1 | |
| SCHEMBL21990727 | 0.86 | CDKN1A (0.53) | MAPTTDP1NR3C1CDKN1AMAPK1 | |
| SCHEMBL22060151 | 0.86 | ABCB1 (0.44) | NR3C1TRPV1CDKN1AP2RY1SMN1; SMN2 | |
| SCHEMBL22060178 | 0.85 | CDKN1A (0.49) | MAPTNR3C1CDKN1AMAPK1SMN1; SMN2 | |
| SCHEMBL22060403 | 0.84 | NR3C1 (0.43) | MAPTTDP1NR3C1CDKN1AMAPK1 | |
| SCHEMBL23746410 | 0.83 | CDKN1A (0.47) | MAPTTDP1NR3C1CDKN1AMAPK1 | |
| SCHEMBL22060181 | 0.83 | CDKN1A (0.44) | MAPTNR3C1CDKN1ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210244712-A1 | METHODS FOR TREATING PATIENTS WITH CANCER HAVING DEFECTS IN CYCLIN D REGULATION | NYSNOBIO IRELAND DAC (IE) | 2021-08-12 | — | — | US | disclosed |
| US-20210230126-A1 | ASYMMETRIC TRIAZOLE BENZAMIDE DERIVATIVES AND THE COMPOSITIONS AND METHODS OF TREATMENT REGARDING THE SAME | NYSNOBIO IRELAND DAC (IE) | 2021-07-29 | — | — | US | disclosed |
| US-10889553-B2 | Asymmetric triazole benzamide derivatives and the compositions and methods of treatment regarding the same | NYSNOBIO IRELAND DAC (IE) | 2021-01-12 | — | — | US | disclosed |
| US-20200172497-A1 | ASYMMETRIC TRIAZOLE BENZAMIDE DERIVATIVES AND THE COMPOSITIONS AND METHODS OF TREATMENT REGARDING THE SAME | NYSNOBIO IRELAND DAC (IE) | 2020-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210244712-A1 | METHODS FOR TREATING PATIENTS WITH CANCER HAVING DEFECTS IN CYCLIN D REGULATION | TP53, RB1, CDK1 | MAPT 3369/4885TDP1 854/4885NR3C1 1610/4885 |
| US-20200172497-A1 | ASYMMETRIC TRIAZOLE BENZAMIDE DERIVATIVES AND THE COMPOSITIONS AND METHODS OF TREATMENT REGARDING THE SAME | ATG7, PINK1, ADRM1 | MAPT 1670/4885TDP1 1095/4885NR3C1 3027/4885 |
| US-20210230126-A1 | ASYMMETRIC TRIAZOLE BENZAMIDE DERIVATIVES AND THE COMPOSITIONS AND METHODS OF TREATMENT REGARDING THE SAME | ATG7, PINK1, ADRM1 | MAPT 1670/4885TDP1 1095/4885NR3C1 3027/4885 |
| US-10889553-B2 | Asymmetric triazole benzamide derivatives and the compositions and methods of treatment regarding the same | ATG7, PINK1, ADRM1 | MAPT 1670/4885TDP1 1095/4885NR3C1 3027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.